Welcome to our dedicated page for WORK Medical Technology Group SEC filings (Ticker: WOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The WORK Medical Technology Group LTD (WOK) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer in the medical devices sector. WORK Medical files annual reports on Form 20-F and current reports on Form 6-K, detailing its operations in developing and manufacturing Class I and II medical devices and selling Class I and II disposable medical devices through subsidiaries in China.
In these filings, investors can review information on WORK Medical’s product portfolio of medical consumables and equipment, its sales footprint across 34 provincial-level administrative regions in China, and the registration of 17 products with the U.S. Food and Drug Administration. Form 6-K reports provide updates on interim financial statements and management’s discussion and analysis, extraordinary general meetings and voting results, changes in independent auditors, and capital markets transactions such as registered direct offerings, at-the-market sales agreements, and pre-funded warrants.
Filings also describe share structure changes and Nasdaq listing matters, including approved share consolidations (reverse stock splits), increases in authorized share capital, and correspondence with Nasdaq regarding minimum bid price compliance and potential delisting determinations. These documents outline the reasons for share consolidations, effective dates, and post-consolidation share counts, giving context to changes in the company’s capital structure.
On Stock Titan, users can access WORK Medical’s Forms 6-K and 20-F as they are furnished to the SEC’s EDGAR system, along with AI-powered summaries that highlight key points such as financing terms, governance changes, and listing status updates. The filings page is also a reference point for tracking any future registration statements, prospectus supplements, and other transactional documents that the company incorporates by reference into its shelf registration statements.
WORK Medical Technology Group LTD reports a change in its board of directors. On March 23, 2026, independent director Xiaoyang Li resigned from the Board, the Audit, Compensation, and Nominating and Corporate Governance Committees, and as chairperson of the Compensation Committee, citing personal reasons.
To fill this vacancy, the Board appointed Dr. Qisheng Lin as an independent director, a member of all three committees, and chairperson of the Compensation Committee, effective the same day. Dr. Lin is a nephrology specialist and academic with roles at Renji Hospital and prior research experience at the Icahn School of Medicine at Mount Sinai. The Board determined he meets the Nasdaq “independent director” standard. This report is incorporated by reference into the Company’s Form F-3 registration statement (File No. 333-289943).
WORK Medical Technology Group LTD filed Amendment No. 1 to its Form 20-F as an exhibit-only update. The amendment’s sole purpose is to add Exhibit 15.2 and Exhibit 15.3, which are consents from its independent auditors, WWC, P.C. and HTL International, LLC.
The company states that no other changes were made to the previously filed annual report for the year ended September 30, 2025, and that this amendment does not update any disclosures or reflect later events. As of September 30, 2025, the company had 95,998,776 Class A and 7,592,500 Class B ordinary shares outstanding.
WORK Medical Technology Group reported that shareholders approved all 13 proposals at the annual general meeting, with 2,064,443 votes represented, about 56.73% of total votes as of January 30, 2026.
Shareholders approved a major share capital reorganization. The authorized share capital was first increased to US$100,000,000,000 divided into 16,000,000,000 Class A and 4,000,000,000 Class B ordinary shares, each with a par value of US$5.00. They then approved a reduction of the par value of each issued Class A and Class B share from US$5.00 to US$0.00001, transferring the resulting credit to a distributable reserve that may be used as permitted by law, including offsetting accumulated losses. Following related subdivision and cancellation steps, the authorized share capital will be US$200,000 divided into 16,000,000,000 Class A and 4,000,000,000 Class B ordinary shares, each with a par value of US$0.00001.
Shareholders also authorized a future share consolidation, allowing the board, within two years, to consolidate each 4,000 shares, or a lesser whole share amount not fewer than 2, into 1 share, with fractional entitlements rounded up. Several amended and restated memoranda of association to reflect the capital changes and consolidation were approved. All nominated directors, including LI Xiaoyang and WU Shuang, were re-elected, HTL International, LLC was confirmed as auditor for the fiscal year ending September 30, 2026, and authority to adjourn the meeting if needed was ratified.
WORK Medical Technology Group LTD has called an annual general meeting on February 25, 2026 for shareholders of its Class A and Class B ordinary shares. Investors are being asked to approve a major change to the capital structure, increasing authorized share capital from US$100,000,000 (16,000,000 Class A and 4,000,000 Class B shares at US$5.00 par) to US$100,000,000,000 (16,000,000,000 Class A and 4,000,000,000 Class B shares at US$5.00 par).
The company also seeks a share capital reduction and reorganization, cutting par value on issued shares from US$5.00 to US$0.00001 and ultimately resetting authorized share capital to US$200,000 divided into 16,000,000,000 Class A and 4,000,000,000 Class B shares at US$0.00001 par. The board further requests authority to implement, within two years, a share consolidation (reverse split) of between 2-for-1 and up to 4,000-for-1, mainly to help maintain compliance with Nasdaq’s minimum bid-price rules.
Shareholders will also vote on adopting amended and restated memoranda of association to reflect the capital changes, re-electing five current directors, re-appointing HTL International, LLC as auditor for the year ending September 30, 2026, and granting the board power to adjourn the meeting if more time is needed to secure approvals.
WORK Medical Technology Group LTD files its annual Form 20-F as a Cayman Islands holding company whose operations are conducted entirely through PRC and Hong Kong subsidiaries. Investors in the Nasdaq-listed Class A Ordinary Shares hold equity in the Cayman entity, not directly in the PRC subsidiaries.
The report highlights extensive legal and operational risks from doing business in China, including evolving CSRC filing rules for overseas offerings, potential future cybersecurity or M&A approvals, and possible PRC intervention that could limit operations, capital movements, or future securities offerings and materially reduce share value.
It also warns that under the HFCA Act, an inability of the PCAOB to inspect the company’s U.S.-based auditor for two consecutive years could trigger a trading prohibition and potential Nasdaq delisting, and it explains significant constraints and tax frictions on moving cash and paying dividends from PRC subsidiaries up to the Cayman holding company.
WORK Medical Technology Group LTD entered into a Sales Agreement with AC Sunshine Securities, LLC to allow at-the-market sales of its Class A ordinary shares. These shares may be offered and sold from time to time through the sales agent under a Form F-3 shelf registration, for an aggregate offering price of up to $200,000,000, as described in a prospectus supplement dated November 21, 2025.
The company is not obligated to sell any shares, and the sales agent will use commercially reasonable efforts to execute sales pursuant to the company’s instructions. WORK Medical Technology Group will pay the sales agent a 3.5% commission on the aggregate gross proceeds of any shares sold and will provide customary indemnification and reimburse specified expenses.
WORK Medical Technology Group LTD is launching an at-the-market offering of up to $200,000,000 of Class A ordinary shares through AC Sunshine Securities LLC as sales agent. The company will pay a 3.5% commission on shares sold, and would receive up to approximately $192,820,000 in estimated net proceeds if the full amount is issued, to be used for working capital and general corporate purposes.
The Class A shares trade on the NASDAQ Capital Market under the symbol WOK, and there were 960,012 Class A and 75,925 Class B ordinary shares outstanding as of November 20, 2025. Because each Class B share has 20 votes, the chief operating officer currently controls about 50.43% of the voting power, and selling more than 21,489 new Class A shares would reduce this below 50%.
The filing highlights that investors are buying shares in a Cayman Islands holding company whose operations are conducted through PRC subsidiaries, and details extensive legal, regulatory, and geopolitical risks tied to operating in China and potential U.S. trading restrictions under the HFCA Act.
WORK Medical Technology Group LTD reported the results of its Extraordinary General Meeting of Shareholders. Holders of 154,436,364 Ordinary Shares, representing 247,848,776 votes, were present in person or by proxy, constituting a quorum. Shareholders adopted all resolutions presented.
On the record date of October 15, 2025, there were 95,998,776 Class A ordinary shares outstanding (one vote per share) and 7,592,500 Class B ordinary shares outstanding (20 votes per share).
- Resolution No. 1: For 153,170,658; Against 1,255,575; Abstain 10,131
- Resolution No. 2: For 153,175,624; Against 1,249,460; Abstain 11,280
- Resolution No. 3: For 153,135,917; Against 1,285,427; Abstain 15,020
- Resolution No. 4: For 153,115,501; Against 1,304,198; Abstain 16,665
- Resolution No. 5: For 153,143,787; Against 1,266,563; Abstain 26,014
WORK Medical Technology Group LTD reported it has regained compliance with Nasdaq’s Minimum Bid Price Requirement. Nasdaq confirmed the company maintained a closing bid of $1.00 or greater per Class A ordinary share for 10 consecutive business days, from October 10, 2025 to November 3, 2025.
Nasdaq notified the company on November 4, 2025 that the matter is closed. This follows earlier notices granting time through April 6, 2026 to cure the deficiency under Listing Rule 5550(a)(2).
WORK Medical Technology Group LTD filed a Form 6-K furnishing materials for an extraordinary general meeting of shareholders. The filing provides the meeting notice and proxy statement as Exhibit 99.1 and a proxy card as Exhibit 99.2. These documents will be mailed to shareholders in connection with the meeting.
The company indicates it reports under Form 20-F. The submission is signed by Chief Executive Officer Shuang Wu and dated October 21, 2025.